Ravi K Amaravadi

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician , Hospital of the University of Pennsylvania
Member, Institute of Translational Medicine and Therapeutics
Member, Abramson Cancer Center
Member, University of Pennsylvania GI Center for Molecular Studies of Digestive and Liver Diseases
Co-Leader Cancer Therapeutics Program , Abramson Cancer Center, University of Pennsylvania
Department: Medicine

Contact information
Hematology-Oncology Division
University of Pennsylvania
16 Penn Tower
3400 Spruce St.
Philadelphia, PA 19104
Office: 215-662-7402
Fax: 215-349-8550
Education:
BA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Permanent link
 

Description of Research Expertise

Autophagy, Mechanisms of Cell Death, Developmental Therapeutics

Description of Itmat Expertise

Dr. Amaravadi conducts basic, preclinical and Phase I/II clinical trials in novel molecularly targeted therapeutics and combinations in cancer therapy.

Selected Publications

Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH: Phase I and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in dogs with spontaneously occurring lymphoma. Autophagy 10(8), August 2014.

Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, Bradner JE, Amaravadi RK.: Combined autophagy and proteasome inhibition: Phase I trial of hydroxychloroquine with bortezomib in patients with relapsed refractory multiple myeloma. Autophagy 10(8), August 2014.

Rangwala R, Chang YC, Hu J, Algazy K, Evans T, Fecher L, Schuchter L, Torigian DA, Panosian J, Troxel A, Tan KS, Heitjan DF, Demichele A, Vaughn D, Redlinger M, Alavi A, Kaiser J, Pontiggia L, Davis LE, O'Dwyer PJ, Amaravadi RK.: Combined mTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma Autophagy (2012 IF 12) 10(8), August 2014.

Rangwala R, Leone R, Chang YC, Fecher L, Schuchter L, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel A, Evans T, Demichele A, Nathanson KL, O'Dwyer PJ, Kaiser J, Pontiggia L, Davis LE, Amaravadi RK.: Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma Autophagy 10(8), August 2014.

Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi R, Davis LE, Mita A, Curiel TJ, Espitia CM, Nawrocki ST, Giles FJ, Carew JS.: Combined Inhibition of Autophagy and HDAC inhibition: A Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Analysis of Hydroxychloroquine in Combination with the HDAC Inhibitor Vorinostat in Patients with Advanced Solid Tumors Autophagy (2012 IF 12) 10(8), August 2014.

Choe, C, Mcarthur GA, Yang M, Caro I, Kempen JH, Amaravadi RK: Ocular Toxicity in BRAF Mutant Melanoma Patients Treated With Vemurafenib Am J. Ophthalmology epub ahead of print , Jul 2014.

Ma XH, Piao SF, Dey S, Mcafee Q, Karakousis G, Villaneuva J , Hart LS, Levi S, Hu J, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C,Amaravadi RK.: Targeting ER stress induced-autophagy overcomes resistance to BRAF inhibition in melanoma Journal of Clinical Investigation pii: 70454. doi: 10.1172/JCI70454. [Epub ahead of print] (eds.). March 2014.

Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amavaradi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS.: Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigement Cell and Melanoma Research Feb 2014.

Hubbard-Lucey V, Shono Y,Maurer K,West ML,Singer NV, Ziegler CG, Lezcano, C, Motta AC,Schmid K,Levi SM,Murphy GF,Liu C,Winkler JD,Amaravadi JK,Rogler G,Dickinson AM,Holler E,van den Brink M,Cadwell K: Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells. Immunity Page: http://dx.doi.org/10.1016/j.immuni.2014.09.011, 2014.

Myrna R. Rosenfeld, Jeffrey G. Supko, Stuart A. Grossman, Steven Brem, Tom Mikkelson, Daniel Wang, Claire Chang, Janice Hu, Quentin McAfee, Andrea Troxel, Shengfu Piao, Daniel Hetjian, Kay See Tan, Laura Pontiggia, Peter J. O’Dwyer, Lisa E. Davis, Ravi K.Amaravadi: A Phase I/II Trial of Hydroxychloroquine in Conjunction with Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme Autophagy (2012 IF 12) 2014 Notes: In press.

back to top
Last updated: 11/26/2014
The Trustees of the University of Pennsylvania